Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.

ABSTRACT:

Aims

Sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have cardio-kidney-metabolic benefit. This study aimed to understand the prevalence of prescription of SGLT2 inhibitors and GLP1-RA among patients with T2DM with and without chronic kidney disease (CKD) in Australian primary care.

Materials and methods

We conducted a retrospective, cohort study of adults with T2DM who attended primary care practices participating in MedicineInsight. The outcome of interest was the percentage of patients with CKD who received ≥1 prescription for an SGLT2 inhibitor or a GLP1-RA (assessed separately) compared to those without CKD during 2020-2021. We also assessed prescriptions in a sub-population of CKD patients who met tr

SUBMITTER: Wallace H 

PROVIDER: S-EPMC12409226 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature